Serum hepcidin levels predict response to intravenous iron and darbepoetin in chemotherapy-associated anemia

Blood

Volumn 125, Issue 23, 2015, Pages 3669-3671

  Steensma, David P ^a,d   Sasu, Barbra J ^b   Sloan, Jeff A ^c   Tomita, Dianne K ^b   Loprinzi, Charles L ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b AMGEN INC   (United States)

^c MAYO CLINIC   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FERRIC GLUCONATE; FERRITIN; FERROUS SULFATE; HEPCIDIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; TRANSFERRIN; ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; ERYTHROPOIETIN;

CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; ERYTHROCYTE TRANSFUSION; FERRITIN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON OVERLOAD; IRON STORAGE; LETTER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANEMIA; BLOOD; CHEMICALLY INDUCED; FEMALE; MALE; MULTICENTER STUDY (TOPIC); NEOPLASMS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANEMIA; ANTINEOPLASTIC AGENTS; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEPCIDINS; HUMANS; MALE; MULTICENTER STUDIES AS TOPIC; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84938945033     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-03-636407     Document Type: Letter

References (14)

1. Spivak JL. The anaemia of cancer: death by a thousand cuts. Nat Rev Cancer. 2005;5(7):543-555.
2. Tonia T, Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012;12:CD003407.
3. Tarng DC, Huang TP, Chen TW, Yang WC. Erythropoietin hyporesponsiveness: from iron deficiency to iron overload. Kidney Int Suppl. 1999;69:S107-S118.
4. Besarab A, Coyne DW. Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol. 2010;6(12):699-710.
5. Thomas DW, Hinchliffe RF, Briggs C, Macdougall IC, Littlewood T, Cavill I; British Committee for Standards in Haematology. Guideline for the laboratory diagnosis of functional iron deficiency. Br J Haematol. 2013;161(5):639-648.
6. Auerbach M, Ballard H. Clinical use of intravenous iron: administration, efficacy, and safety. Hematol Am Soc Hematol Educ Program. 2010;2010:338-347.
7. Auerbach M. Intravenous iron in chemotherapy-induced anemia. Am J Hematol. 2014;89(12):1153.
8. Steensma DP, Sloan JA, Dakhil SR, et al. Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapyassociated anemia. J Clin Oncol. 2011;29(1):97-105.
9. Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117(17): 4425-4433.
10. Li H, Rose MJ, Tran L, et al. Development of a method for the sensitive and quantitative determination of hepcidin in human serum using LC-MS/MS. J Pharmacol Toxicol Methods. 2009;59(3):171-180.
11. Shu T, Jing C, Lv Z, Xie Y, Xu J, Wu J. Hepcidin in tumor-related iron deficiency anemia and tumor-related anemia of chronic disease: pathogenic mechanisms and diagnosis. Eur J Haematol. 2015;94(1):67-73.
12. Pinto JP, Ribeiro S, Pontes H, et al. Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C/EBPalpha. Blood. 2008;111(12):5727-5733.
13. Kautz L, Nemeth E. Molecular liaisons between erythropoiesis and iron metabolism. Blood. 2014;124(4):479-482.
14. van Eijk LT, John AS, Schwoebel F, et al. Effect of the antihepcidin Spiegelmer lexaptepid on inflammation-induced decrease in serum iron in humans. Blood. 2014;124(17):2643-2646.